Methods and devices for the production and delivery of beneficial factors from stem cells

Abstract

Provided herein are methods and devices related to inducing a population of self-renewing or senescent stem cells, to produce one or more beneficial factors for the treatment of a disease or disorder in an individual. Also provided are compositions and methods for inducing senescence, useful for inducing senescence in a population of stem cells, in order to produce one or more beneficial factors for the treatment of a disease or disorder in an individual. Methods and devices to control and customize the production of the beneficial factors for the requirements of a disease or disorder being treated are described. Also provided are factor production units for the production of the beneficial factors, and devices for the delivery of the beneficial factors to an individual in need.

1 .- 74 . (canceled) 
     
     
         75 . A method of expanding regulatory T-cell (Tregs), the method comprising:
 growing a population of human adipose derived stem cells (hADSCs);   adding an inducing agent comprising IL-2 to the population of hADSCs for about 24 hours to induce the production of the one or more secreted factors by the population of hADSCs;   collecting the one more secreted factors about 72 hours post-induction; and   contacting peripheral blood mononuclear cells (PBMCs) with the one or more secreted factors to induce expansion of the Tregs.   
     
     
         76 . The method of  claim 75 , wherein the population of hADSCs comprise self-renewing (SR) cells and senescent (SEN) cells. 
     
     
         77 . The method of  claim 75 , wherein the population of hADSCs comprise at least 50% SR cells. 
     
     
         78 . The method of  claim 75 , wherein the population of hADSCs comprise at least 50% SEN cells. 
     
     
         79 . The method of  claim 75 , wherein the secreted factors are produced in a factor production unit. 
     
     
         80 . A method for modulating immune cells, the method comprising:
 providing a population of human adipose derived stem cells (hADSCs);   adding an inducing agent comprising IL-2 to the population of hADSCs for about 24 hours to induce the production of one or more secreted factors by the population of hADSCs;   collecting the one more secreted factors about 72 hours post-induction; and   contacting immune cells of a subject with the one or more secreted factors to immunomodulate the immune cells.   
     
     
         81 . The method of  claim 80 , wherein the one or more secreted factors are administered to a subject. 
     
     
         82 . The method of  claim 80 , wherein the one or more secreted factors are contacted with the immune cells ex vivo. 
     
     
         83 . The method of  claim 82 , wherein the immune cells are collected from a blood sample or a plasma sample from a subject. 
     
     
         84 . The method of  claim 83 , further comprising delivering the immunomodulated immune cells back into the subject. 
     
     
         85 . The method of  claim 80 , wherein the immune cells comprise peripheral blood mononuclear cells (PBMCs). 
     
     
         86 . The method of  claim 80 , wherein the immunomodulated immune cells comprise regulatory T-cell (Tregs). 
     
     
         87 . The method of  claim 85 , wherein the modulating of the immune cells comprises increasing production of the Tregs from the immune cells. 
     
     
         88 . The method of  claim 80 , wherein the population of hADSCs comprise self-renewing (SR) cells and senescent (SEN) cells. 
     
     
         89 . The method of  claim 80 , wherein the population of hADSCs comprise at least 50% SR cells. 
     
     
         90 . The method of  claim 80 , wherein the population of hADSCs comprise at least 50% SEN cells. 
     
     
         91 . The method of  claim 80 , wherein the population of hADSCs are provided in a factor production unit.